Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Migraine (US)
Episodic and chronic migraines are often disabling and reduce patients’ quality of life. Despite triptans’ dominance in the treatment algorithm, many patients respond inadequately, cannot tolerate them, or have cardiovascular contraindications—creating significant unmet need and opportunity for alternative acute treatments. Since 2020, the acute market has diversified beyond vasoconstrictors, led by oral calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) such as AbbVie’s Ubrelvy, Pfizer’s Nurtec ODT, and intranasal zavegepant, expanding options for patients needing rapid, non-oral relief. Competition for fastacting acute treatments has intensified with reformulations of established agents, including Satsuma’s Atzumi (DHE nasal powder) and Amneal’s Brekiya (the first DHE autoinjector), while Axsome Therapeutics’ Symbravo (meloxicam / rizatriptan) targets prior acute / gepant nonresponders. Our quantitative analysis of national patient-level claims data examines the growing uptake of new brands to treat both newly diagnosed and recently treated patients in a market characterized by numerous generic options.
Questions answered
- What patient shares do key acute therapies capture by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing among newly diagnosed and recently treated patients?
- How have oral CGRP receptor antagonists been integrated into the acute treatment algorithm, and what is their source of business?
- What percentage of migraine patients initiate acute drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of acute treatments within the same period?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy
- Evaluate your brand share against competitors
- Accurately assess your source of business
- Quantify opportunities at different stages of the treatment algorithm
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Key drugs covered:
Ubrelvy, Nurtec ODT, Reyvow, Elyxyb, Zavzpret, Zembrace SymTouch, Onzetra Xsail, sumatriptan, zolmitriptan, rizatriptan, and other FDA-approved acute antimigraine therapies
Key analyses:
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow charts
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
